These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

726 related articles for article (PubMed ID: 25045276)

  • 21. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-alcoholic steatohepatitis: new insights from OMICS studies.
    Martel C; Esposti DD; Bouchet A; Brenner C; Lemoine A
    Curr Pharm Biotechnol; 2012 Apr; 13(5):726-35. PubMed ID: 22122481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin resistance in nonalcoholic fatty liver disease.
    Bugianesi E; Moscatiello S; Ciaravella MF; Marchesini G
    Curr Pharm Des; 2010 Jun; 16(17):1941-51. PubMed ID: 20370677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations.
    Milić S; Lulić D; Štimac D
    World J Gastroenterol; 2014 Jul; 20(28):9330-7. PubMed ID: 25071327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phytotherapy as Multi-Hit Therapy to Confront the Multiple Pathophysiology in Non-Alcoholic Fatty Liver Disease: A Systematic Review of Experimental Interventions.
    Ore A; Akinloye OA
    Medicina (Kaunas); 2021 Aug; 57(8):. PubMed ID: 34441028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p53 as a double-edged sword in the progression of non-alcoholic fatty liver disease.
    Yan Z; Miao X; Zhang B; Xie J
    Life Sci; 2018 Dec; 215():64-72. PubMed ID: 30473026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology.
    Loria P; Marchesini G; Nascimbeni F; Ballestri S; Maurantonio M; Carubbi F; Ratziu V; Lonardo A
    Atherosclerosis; 2014 Jan; 232(1):99-109. PubMed ID: 24401223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-alcoholic fatty liver disease: The diagnosis and management.
    Abd El-Kader SM; El-Den Ashmawy EM
    World J Hepatol; 2015 Apr; 7(6):846-58. PubMed ID: 25937862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease.
    Mato JM; Alonso C; Noureddin M; Lu SC
    World J Gastroenterol; 2019 Jun; 25(24):3009-3020. PubMed ID: 31293337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-alcoholic steatohepatitis.
    Schröder T; Kucharczyk D; Bär F; Pagel R; Derer S; Jendrek ST; Sünderhauf A; Brethack AK; Hirose M; Möller S; Künstner A; Bischof J; Weyers I; Heeren J; Koczan D; Schmid SM; Divanovic S; Giles DA; Adamski J; Fellermann K; Lehnert H; Köhl J; Ibrahim S; Sina C
    Mol Metab; 2016 Apr; 5(4):283-295. PubMed ID: 27069868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.
    Schuppan D; Schattenberg JM
    J Gastroenterol Hepatol; 2013 Aug; 28 Suppl 1():68-76. PubMed ID: 23855299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Knockdown of long non-coding RNA Gm10804 suppresses disorders of hepatic glucose and lipid metabolism in diabetes with non-alcoholic fatty liver disease.
    Li T; Huang X; Yue Z; Meng L; Hu Y
    Cell Biochem Funct; 2020 Oct; 38(7):839-846. PubMed ID: 32212193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
    Ota T
    Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine.
    Noureddin M; Mato JM; Lu SC
    Exp Biol Med (Maywood); 2015 Jun; 240(6):809-20. PubMed ID: 25873078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.
    Bellanti F; Villani R; Facciorusso A; Vendemiale G; Serviddio G
    Free Radic Biol Med; 2017 Oct; 111():173-185. PubMed ID: 28109892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular mechanisms of steatosis in nonalcoholic fatty liver disease.
    Pettinelli P; Obregón AM; Videla LA
    Nutr Hosp; 2011; 26(3):441-50. PubMed ID: 21892559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multi-targeting strategy to ameliorate high-fat-diet- and fructose-induced (western diet-induced) non-alcoholic fatty liver disease (NAFLD) with supplementation of a mixture of legume ethanol extracts.
    Koh YC; Lin YC; Lee PS; Lu TJ; Lin KY; Pan MH
    Food Funct; 2020 Sep; 11(9):7545-7560. PubMed ID: 32815965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non alcoholic fatty liver disease and metabolic syndrome.
    Paschos P; Paletas K
    Hippokratia; 2009 Jan; 13(1):9-19. PubMed ID: 19240815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of vascular adhesion protein-1 modifies hepatic steatosis
    Shepherd EL; Karim S; Newsome PN; Lalor PF
    World J Hepatol; 2020 Nov; 12(11):931-948. PubMed ID: 33312420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Causes of Mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol Related Fatty Liver Disease (AFLD).
    Johnston MP; Patel J; Byrne CD
    Curr Pharm Des; 2020; 26(10):1079-1092. PubMed ID: 32003662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.